Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PRIMER-1 Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC)

NCT05185739 is registered in ClinicalTrials.gov with University College, London as lead sponsor.

NCT NCT05185739
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05185739 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PRIMER-1 Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC)
Lead sponsor
University College, London
Phase
Phase 2
Overall status
Recruiting
Start date
August 25, 2022
Completion date
July 31, 2030
Enrollment
60 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma